Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance

Anti-Cancer Agents in Medicinal Chemistry - United Arab Emirates
doi 10.2174/187152012799015002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer

The Open Breast Cancer Journal
2009English

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Preliminary Safety Data of Preoperative Chemotherapy Plus Trastuzumab, Lapatinib or Both in HER2-positive Operable Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2007English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer Research
Cancer ResearchOncology
2009English

P38 MAPK Contributes to Resistance and Invasiveness of HER2- Overexpressing Breast Cancer

Current Medicinal Chemistry
Organic ChemistryBiochemistryDrug DiscoveryMolecular MedicinePharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy